- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01638312
Development of Method of Fructose Identification in Urine to Detect the Viral Infection
The Development of Fast and Simple Method of Fructose Identification in Urine to Detect the Viral Infection in Early Stage
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 807
- Tropical Medicine Center, Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV infection
Exclusion Criteria:
- who are in highly active antiretroviral therapy(HARRT) therapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
HIV infection patient and health people
The study does not have intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fructose Identification in Urine to Detect the Viral Infection : Number of Participants With Positive and Negative Waveform
Time Frame: Participants provided urine samples once
|
This detection technique, after a viral infection caused by the use of cell pathological changes and urine metabolic waste - fructose concentration, derivatives.Health News voltage changes to detect viral pathogens of activity and virulence. Because viral infection caused by the voltage change has its typical, So you can use voltage measurements to calibrate the presence and activity of a viral infection. 1.How to interpretation the data The gap between values on X-axis is σ, and 50 is a reference to the center position. For example, the sample maybe contain with HIV virus if σ≧10 units. σ≧10 abnormal positive (+) σ<10 normal negative (-) |
Participants provided urine samples once
|
Collaborators and Investigators
Investigators
- Principal Investigator: JihJin Tsai, MD, The Medicines Company
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Virus Diseases
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- KMUH-IRB-20110188
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.